GAMMA Investing’s Astria Therapeutics ATXS Stock Holding History

GAMMA Investing’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-620	Closed	-$8.12K	–	4118
2025 Q4	$8.12K	Buy	620 +391	+171%	+$4.67K	﹤0.01%	3076
2025 Q3	$1.67K	Sell	229 -357	-61%	-$2.42K	﹤0.01%	3498
2025 Q2	$3.14K	Sell	586 -1,039	-64%	-$5.04K	﹤0.01%	3277
2025 Q1	$8.68K	Buy	1,625 +918	+130%	+$6.42K	﹤0.01%	2818
2024 Q4	$6.32K	Buy	707 +88	+14%	+$935	﹤0.01%	2816
2024 Q3	$6.82K	Buy	619 +170	+38%	+$1.89K	﹤0.01%	2616
2024 Q2	$4.09K	Sell	449 -8	-2%	-$78	﹤0.01%	2646
2024 Q1	$6.43K	Buy	457 +25	+6%	+$311	﹤0.01%	2294
2023 Q4	$5.63K	Buy	+432	New	+$2.39K	﹤0.01%	2182

GAMMA Investing's ATXS Position: Q1 2026 in Review

GAMMA Investing sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 620 shares — an estimated $8.12K sold.

GAMMA Investing first reported a position in ATXS in Q4 2023 and held it in 9 quarters. The position peaked at $8.68K in Q1 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

GAMMA Investing reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
GAMMA Investing sold 620 Astria Therapeutics shares in Q1 2026, an estimated $8.12K.
GAMMA Investing first reported a position in Astria Therapeutics in Q4 2023 and held it in 9 quarters.
GAMMA Investing's Astria Therapeutics position peaked at $8.68K in Q1 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.